Please assess the completion status of the following clinical trial:

Trial Title: The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* May not have been treated with GLM prior to study enrollment~* Must be able to provide retrospective data concerning extra-articular manifestations and episodes with a recall period of at least 12 months prior to anti-TNF use~* Must have definite AS according to the modified New York criteria in the Netherlands~* Must be candidate for treatment with anti-TNF agent according to the Assessment of SpondyloArthritis International Society (ASAS) consensus~* Must be able to adhere to dose and visit schedules~Exclusion Criteria:~* Any exclusion criteria stated in the Summary of Product Characteristics for golimumab~* Use of any investigational biological or chemical agents within 30 days or 2 half-lives (whichever is longest) of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLM 50 mg (Type: EXPERIMENTAL): GLM given subcutaneously at a dose of 50 mg once monthly for up to 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).